Ciliatech SAS received a U.S. FDA investigational device exemption (IDE) to begin a feasibility study of its Intercil Uveal Spacer implant for glaucoma. The IDE allows the company to test the implant in a regulated clinical setting, moving the spacer design closer to broader development steps depending on safety and performance signals. The study update highlights continued med-tech innovation aimed at reducing treatment burden and adherence challenges in chronic ophthalmic care. It also fits a broader theme of implants that seek to simplify long-term management. For Ciliatech, the IDE is an execution milestone that can accelerate site recruitment and define the data package needed for future pivotal efforts.